Literature DB >> 23683829

Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review.

Alysa Fairchild1, William Straube, Fran Laurie, David Followill.   

Abstract

Central review of radiation therapy (RT) delivery within multicenter clinical trials was initiated in the early 1970s in the United States. Early quality assurance publications often focused on metrics related to process, logistics, and timing. Our objective was to review the available evidence supporting correlation of RT quality with clinical outcomes within cooperative group trials. A MEDLINE search was performed to identify multicenter studies that described central subjective assessment of RT protocol compliance (quality). Data abstracted included method of central review, definition of deviations, and clinical outcomes. Seventeen multicenter studies (1980-2012) were identified, plus one Patterns of Care Study. Disease sites were hematologic, head and neck, lung, breast, and pancreas. Between 0 and 97% of treatment plans received an overall grade of acceptable. In 7 trials, failure rates were significantly higher after inadequate versus adequate RT. Five of 9 and 2 of 5 trials reported significantly worse overall and progression-free survival after poor-quality RT, respectively. One reported a significant correlation, and 2 reported nonsignificant trends toward increased toxicity with noncompliant RT. Although more data are required, protocol-compliant RT may decrease failure rates and increase overall survival and likely contributes to the ability of collected data to answer the central trial question.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23683829      PMCID: PMC3749289          DOI: 10.1016/j.ijrobp.2013.03.036

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

Review 1.  Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials.

Authors:  Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter
Journal:  J Natl Cancer Inst       Date:  2013-03-06       Impact factor: 13.506

2.  Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer.

Authors:  S M Bentzen; J Bernier; J B Davis; J C Horiot; G Garavaglia; J Chavaudra; K A Johansson; M Bolla
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

3.  Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?

Authors:  A Fairchild; L Collette; C W Hurkmans; B Baumert; D C Weber; A Gulyban; P Poortmans
Journal:  Eur J Cancer       Date:  2012-07-04       Impact factor: 9.162

4.  Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

Authors:  E Dühmke; J Franklin; M Pfreundschuh; S Sehlen; N Willich; U Rühl; R P Müller; P Lukas; A Atzinger; U Paulus; B Lathan; U Rüffer; M Sieber; J Wolf; A Engert; A Georgii; S Staar; R Herrmann; M Beykirch; H Kirchner; A Emminger; R Greil; E Fritsch; P Koch; A Drochtert; O Brosteanu; D Hasenclever; M Loeffler; V Diehl
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

5.  Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview.

Authors:  G van Tienhoven; B J Mijnheer; H Bartelink; D G González
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

6.  Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study.

Authors:  C J Fabian; C M Mansfield; S Dahlberg; S E Jones; T P Miller; E Van Slyck; P N Grozea; F S Morrison; C A Coltman; R I Fisher
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

7.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals.

Authors:  J J Kinzie; G E Hanks; C J MacLean; S Kramer
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

9.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.

Authors:  Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

10.  Credentialing for participation in clinical trials.

Authors:  David S Followill; Marcia Urie; James M Galvin; Kenneth Ulin; Ying Xiao; Thomas J Fitzgerald
Journal:  Front Oncol       Date:  2012-12-26       Impact factor: 6.244

View more
  33 in total

1.  Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

Authors:  Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-03       Impact factor: 7.038

Review 2.  Personalized radiotherapy: concepts, biomarkers and trial design.

Authors:  A H Ree; K R Redalen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

3.  Impact of the introduction of weekly radiotherapy quality assurance meetings at one UK cancer centre.

Authors:  C V Brammer; L Pettit; R Allerton; M Churn; M Joseph; P Koh; I Sayers; M King
Journal:  Br J Radiol       Date:  2014-09-24       Impact factor: 3.039

Review 4.  Value: a framework for radiation oncology.

Authors:  Sewit Teckie; Susan A McCloskey; Michael L Steinberg
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 5.  Automated Radiation Treatment Planning for Cervical Cancer.

Authors:  Dong Joo Rhee; Anuja Jhingran; Kelly Kisling; Carlos Cardenas; Hannah Simonds; Laurence Court
Journal:  Semin Radiat Oncol       Date:  2020-10       Impact factor: 5.934

6.  The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial.

Authors:  Ying Xiao; Mark Rosen
Journal:  Transl Lung Cancer Res       Date:  2017-12

7.  Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.

Authors:  Matthew Koshy; Renuka Malik; Usama Mahmood; Zain Husain; Ralph R Weichselbaum; David J Sher
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

Review 8.  Imaging and Data Acquisition in Clinical Trials for Radiation Therapy.

Authors:  Thomas J FitzGerald; Maryann Bishop-Jodoin; David S Followill; James Galvin; Michael V Knopp; Jeff M Michalski; Mark A Rosen; Jeffrey D Bradley; Lalitha K Shankar; Fran Laurie; M Giulia Cicchetti; Janaki Moni; C Norman Coleman; James A Deye; Jacek Capala; Bhadrasain Vikram
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-24       Impact factor: 7.038

Review 9.  The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols.

Authors:  Thomas J FitzGerald; Maryann Bishop-Jodoin; Fran Laurie; Elizabeth O'Meara; Christine Davis; Jeffrey Bogart; John Kalapurakal; Marilyn J Siegel; Bapsi Chakravarthy; Paul Okunieff; Bruce Haffty; Jeff Michalski; Kenneth Ulin; David S Followill; Stephen Kry; Michael Knopp; Jun Zhang; Don Rosen; Mark Rosen; Ying Xiao; Lawrence Schwartz; Janaki Moni; Maria Giulia Cicchetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-10-18       Impact factor: 7.038

10.  Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning.

Authors:  Kelly C Younge; Robin B Marsh; Dawn Owen; Huaizhi Geng; Ying Xiao; Daniel E Spratt; Joseph Foy; Krithika Suresh; Q Jackie Wu; Fang-Fang Yin; Samuel Ryu; Martha M Matuszak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-04       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.